| Literature DB >> 27895058 |
Hartmut Döhner1, Elihu Estey2, David Grimwade3, Sergio Amadori4, Frederick R Appelbaum2, Thomas Büchner5, Hervé Dombret6, Benjamin L Ebert7, Pierre Fenaux8, Richard A Larson9, Ross L Levine10, Francesco Lo-Coco4, Tomoki Naoe11, Dietger Niederwieser12, Gert J Ossenkoppele13, Miguel Sanz14, Jorge Sierra15, Martin S Tallman10, Hwei-Fang Tien16, Andrew H Wei17,18, Bob Löwenberg19, Clara D Bloomfield20.
Abstract
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27895058 PMCID： PMC5291965 DOI： 10.1182/blood-2016-08-733196
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113